What is Roth Capital’s Estimate for TLSI Q3 Earnings?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at Roth Capital issued their Q3 2024 earnings per share (EPS) estimates for TriSalus Life Sciences in a report issued on Monday, November 11th. Roth Capital analyst J. Wittes expects that the company will post earnings per share of ($0.35) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.50) per share. Roth Capital also issued estimates for TriSalus Life Sciences’ Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.47) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.19) EPS.

TLSI has been the subject of several other reports. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday. They set a “buy” rating and a $11.00 price target for the company. Oppenheimer began coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Buy” and an average target price of $12.25.

TriSalus Life Sciences Stock Up 0.9 %

Shares of NASDAQ TLSI opened at $4.50 on Wednesday. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42. The stock has a fifty day simple moving average of $4.39 and a 200-day simple moving average of $5.86.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million during the quarter.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Duquesne Family Office LLC grew its holdings in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the period. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $1,184,000. Finally, Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 32.80% of the stock is currently owned by insiders.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.